Abstract

Editorial

Indian spices and Caffeine treatment for Obesity and Cardiovascular disease

Ian James Martins*

Published: 31 January, 2018 | Volume 2 - Issue 1 | Pages: 010-014

The global obesity epidemic that was previously reported [1,2] is now to worsen with obesity to double in 73 countries around the world [3,4]. Improving the health of obese individuals by dietary restriction, anti-obese foods and increased physical activity [1] has not reduced the global obesity epidemic. Obesity is linked to nonalcoholic fatty liver disease (NAFLD) [5,6] with complications relevant to the metabolic syndrome and cardiovascular disease [7]. Appetite control has become critical to endocrinology and metabolism with the apelinergic pathway and nuclear receptor Sirtuin 1 (Sirt 1) now connected to the endocrine system [8] and critical to metabolism. The apelin-Sirt 1 interaction involves nitric oxide (NO) [9] that is now considered as the defect [10] in the interaction between the peptide apelin and calorie sensitive gene Sirt 1 involved in NO imbalances in the adipose tissue, liver and the brain.

Read Full Article HTML DOI: 10.29328/journal.acem.1001005 Cite this Article Read Full Article PDF

Keywords:

Neuroendocrine system; Metabolism; Adipose tissue; Liver; Mitphagy; NAFLD; Obesity; Apelin; Sirtuin 1; Nitric oxide; Autoimmune disease; Caffeine; Cardiovascular disease; Curcumin; Cinnamon

References

  1. Appetite dysregulation and obesity inWestern Countries. LAP LAMBERT Academic Publishing. 2013. Ref.: https://goo.gl/9Q9tnW
  2. Martins IJ. Induction ofNAFLD with Increased Risk of Obesity and Chronic Diseases in DevelopedCountries. OJEM Diseases. 2014; 4: 90-110. Ref.: https://goo.gl/uHz7H6
  3. An R, Ji M, Zhang S. Global warming and obesity: a systematicreview. Obes Rev. 2018; 19: 150-163. Ref.: https://goo.gl/i9GpEv
  4. Friedrich MJ. Global Obesity Epidemic Worsening. JAMA.2017; 318:603. Ref.: https://goo.gl/79iEGw
  5. Fabbrini E, Sullivan S,Klein S. Obesity and non-alcoholicfatty liver disease: biochemical, metabolic, and clinical implications. Hepatology.2010; 51: 679-689. Ref.: https://goo.gl/ebJjFZ
  6. DietrichP, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and themetabolic syndrome. Best Pract Res Clin Gastroenterol. 2014; 28: 637-653.Ref.: https://goo.gl/ecCzVn
  7. Kim SH, Després JP, Koh KK. Obesity and cardiovascular disease:friend or foe? Eur Heart J. 2016; 37: 3560-3568. Ref.: https://goo.gl/4ZjohT
  8. Martins IJ. Nutritionaldiets accelerate amyloid beta metabolism and prevent the induction ofchronic diseases and Alzheimer’s disease. J Endocrinol andMetab. Photon. 2015; 1-48.
  9. Martins IJ. Apelin andSirtuin 1 dysregulation induce Endocrine and Metabolic Disorders inChronic disease. GJEM. 2017; 1:1. Ref.: https://goo.gl/Z3TmLM
  10. Apelinergic System Defects with Relevance to Mental Disorders inDiabetes. World J Psychiatry Ment Health Res. 2017; 1: 1001. Ref.: https://goo.gl/q3yoRr
  11. Martins IJ. UnhealthyNutrigenomic Diets Accelerate NAFLD and Adiposity in Global communities. JMol Genet Med. 2015; 9: 1-8. Ref.: https://goo.gl/mWnRMX
  12. QureshiK, Abrams GA. Metabolic liver disease of obesity and role of adiposetissue in the pathogenesis of nonalcoholic fatty liver disease. World JGastroenterol. 2007; 13: 3540-3553. Ref.: https://goo.gl/56N5AG
  13. Martins IJ. Avasimibe andSirt 1 Activators Reverse NAFLD and Obesity. Nov Appro Drug Des Dev. 2017;1: 1-2.
  14. Mechanisms underlying current and future anti-obesity drugs. TrendsNeurosci. 2013; 36: 133-40. Ref.: https://goo.gl/1n2Ha4
  15. García-RuizC, Baulies A, Mari M, García-Rovés PM, Fernandez-Checa JC. Mitochondrialdysfunction in non-alcoholic fatty liver disease and insulin resistance:cause or consequence?Free Radic Res. 2013; 47: 854-868.Ref.: https://goo.gl/iwfFy7
  16. Martins IJ. Defective Inter­playbetween Adipose Tissue and Immune System Induces Non Alcoholic Fatty LiverDisease. Updates Nutr Disorders Ther. 2017; 1: 3.1. Ref.: https://goo.gl/YQSnyd
  17. Martins IJ. Autoimmunedisease and mitochondrial dysfunction in chronic diseases.Res Chron Dis.2017; 1: 10-12. Ref.: https://goo.gl/LXak5D
  18. MazzucotelliA, Ribet C, Castan-Laurell I, Daviaud D, Guigné C, et al. Thetranscriptional co-activator PGC-1alpha up regulates apelin in human andmouse adipocytes. Regul Pept. 2008; 150: 33-37. Ref.: https://goo.gl/rJtdLa
  19. KilicU, Gok O, Bacaksiz A, Izmirli M, Elibol-Can B, et al. SIRT1gene polymorphisms affect the protein expression in cardiovasculardiseases. PLoS One. 2014; 9: 90428. Ref.: https://goo.gl/3Y8B9Y
  20. Biason-Lauber A, Böni-Schnetzler M, HubbardBP, Bouzakri K, Brunner A, etal. Identification of a SIRT1Mutation in a Family with Type 1 Diabetes. Cell Metab. 2013; 17: 448-455.Ref.: https://goo.gl/xjz2Qm
  21. Hughes JW, Herold KC. Novel SIRT1 MutationLinked to Autoimmune Diabetes in Humans. Cell Metab. 2013; 17: 311-312. Ref.: https://goo.gl/NQ5rtv
  22. Type 3 diabetes with links to NAFLD and Other Chronic Diseases in theWestern World. Int J Diab and Metab Disord. 2016; 1: 1-5. Ref.: https://goo.gl/hGqXFe
  23. Martins IJ. Heat shock gene Sirtuin 1 regulatespost-prandial lipid metabolism with relevance to nutrition and appetiteregulation in diabetes. Int J Diab Clin Diagn. 2016; 3: 1-3. Ref.: https://goo.gl/WdzCgC
  24. Martins IJ. Regulation ofCore Body Temperature and the Immune System Determines Species Longevity.Curr Updates Gerontol. 2017; 1: 6. Ref.: https://goo.gl/y3tCqE
  25. Martins IJ. CaffeineConsumption and Induction of Obesity in the Developed World. Ann ObesDisord. 2017; 2: 1018. https://goo.gl/km1Unh
  26. Martins IJ. NutritionTherapy Regulates Caffeine Metabolism with Relevance to NAFLD andInduction of Type 3 Diabetes. J Diabetes Metab Disord. 2017; 4: 019. Ref.: https://goo.gl/ukJA55
  27. Caffeine with Links to NAFLDand Accelerated Brain Aging. In Tech Open. 2017. Ref.: https://goo.gl/8dZsGD
  28. Martins IJ. Caffeineconsumption with Relevance to Type 3 diabetes and accelerated brain aging.Res Reveiws: Neurosci. 2016; 1: 1-5. Ref.: https://goo.gl/qbUzY8
  29. Martins IJ. Indian Spicesand Unhealthy Diets interfere with Drug Therapy in Diabetes andNeurodegenerative Diseases. Nov Appro Drug Des Dev. 2018; 3: 1-4. Ref.: https://goo.gl/H5YZN4
  30. EjazA, Wu D, Kwan P, Meydani M. Curcumin inhibits adipogenesis in 3T3-L1adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr. 2009; 139:919-925. Ref.: https://goo.gl/XspCuq
  31. TeichT, Pivovarov JA, Porras DP, Dunford EC, Riddell MC. Curcumin limits weightgain, adipose tissue growth, and glucose intolerance following thecessation of exercise and caloric restriction in rats. J Appl Physiol(1985). 2017; 123: 1625-1634. Ref.: https://goo.gl/djjGKY
  32. WangS, Wang X, Ye Z, Xu C, Zhang M, et al. Curcumin promotes browning of whiteadipose tissue in a norepinephrine-dependent way. Biochem Biophys ResCommun. 2015; 466: 247-253. Ref.: https://goo.gl/SuiirT
  33. Curcumin and obesity.Biofactors. 2013; 39: 78-87. Ref.: https://goo.gl/wkqhdv
  34. InzaugaratME, De Matteo E, Baz P, Lucero D, García CC, et al. New evidence for thetherapeutic potential of curcumin to treat nonalcoholic fatty liverdisease in humans. PLoS ONE. 2017; 12: e0172900. Ref.: https://goo.gl/C5CdXU
  35. PanahiY, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, et al. Efficacyand Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: ARandomized Controlled Trial. Drug Res (Stuttg). 2017; 67: 244-251. Ref.: https://goo.gl/QzbkiS
  36. RahmaniS, Asgary S, Askari G, Keshvari M, Hatamipour M, et al.Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A RandomizedPlacebo-controlled Trial. Phytother Res. 2016; 30: 1540-1548. Ref.: https://goo.gl/oBQ7j7
  37. BaligaMS, Jagetia GC, Rao SK, Babu K. Evaluation of nitric oxide scavengingactivity of certain spices in vitro: a preliminary study. Nahrung. 2003; 47:261-264. Ref.: https://goo.gl/97anfL
  38. KalaivaniP, Saranya RB, Ramakrishnan G, Ranju V, Sathiya S, et al. Cuminum cyminum,a dietary spice, attenuates hypertension via endothelial nitric oxidesynthase and NO pathway in renovascular hypertensive rats. Clin ExpHypertens. 2013; 35: 534-542. Ref.: https://goo.gl/R5V2P9
  39. Nakatake R, Hishikawa H,Matsuhima H, Nakamura Y, Ishizaki M, et al. Curcumin protects liverinflammation by suppressing expression of inducible nitric oxide synthasein primary cultured rat hepatocytes. Functional Foods in Health andDisease. 2017; 7: 716-734. Ref.: https://goo.gl/CyxUaA
  40. CalabreseV, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, et al. Redoxregulation of heat shock protein expression in aging and neurodegenerativedisorders associated with oxidative stress: a nutritional approach. AminoAcids. 2003; 25: 437-444. Ref.: https://goo.gl/kZ3LvS
  41. MaitP, Manna J. Activation of Heat Shock Proteins by Nanocurcumin to PreventNeurodegenerative Diseases. Brain Disord Ther. 2014; 3:139. Ref.: https://goo.gl/vSsgkU
  42. Martins IJ. CalorieSensitive Anti-Aging Gene Regulates Hepatic Amyloid Beta Clearance inDiabetes and Neurodegenerative Diseases. EC Nutrition ECO. 2017; 01: 30-32.Ref.: https://goo.gl/FswPeB
  43. ShatwanIA, Ahmed LA, Badkook MM. Effect of barley flour, crude cinnamon, andtheir combination on glycemia, dyslipidemia, and adipose tissue hormonesin type 2 diabetic rats. J Med Food. 2013; 16: 656-662. Ref.: https://goo.gl/uvZt6j
  44. LopesBP, Gaique TG, Souza LL, Paula GS, Kluck GE, et al. Cinnamon extractimproves the body composition and attenuates lipogenic processes in theliver and adipose tissue of rats. Food Funct. 2015; 6: 3257-3265. Ref.: https://goo.gl/5bCMBm
  45. Kwan HY, Wu J, Su T, ChaoX-C, Liu B, et al. Cinnamon induces browning in subcutaneous adipocytes.Scientific Reports. 2017; 7: 2447. Ref.: https://goo.gl/NGzgYy
  46. AskariF, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits onlipid profile, liver enzymes, insulin resistance, and high-sensitivityC-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res.2014; 34: 143-148. Ref.: https://goo.gl/hCkdx7
  47. Hekmatdoost A. Prevention of Nonalcoholic FattyLiver Disease (NAFLD) Progression to Nonalcoholic Steatohepatitis (NASH)by Modification of Lifestyle and Dietary Supplements. J Clin Nutr Diet.2016; 2: 2. Ref.: https://goo.gl/rRi7VN
  48. EslamparastT, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietarysupplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015; 7:204-212. Ref.: https://goo.gl/C6dmCa
  49. Martins IJ. Insulin TherapyInactivation is connected to NAFLD and Diabetes Severity Index. J DiabClin Stud. 2017; 1: 001-003. Ref.: https://goo.gl/zXAMW3
  50. WilsonPW, Bloom HL. Caffeine Consumption and Cardiovascular Risks: Little Causefor Concern. J Am Heart Assoc. 2016; 5: 003089. Ref.: Ref.: https://goo.gl/mQymj7
  51. DingM, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. Long-term coffeeconsumption and risk of cardiovascular disease: a systematic review and adose-response meta-analysis of prospective cohort studies. Circulation.2014; 129: 643-659. Ref.: https://goo.gl/eY1FgP
  52. Martins IJ. Genomic Medicine and Acute Cardiovascular Disease Progression. Res Chron Dis. 2018.

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?